Shin Nippon Biomedical Laboratories Ltd operates within the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Shin Nippon Biomedical Laboratories Ltd with three other
companies in this sector in Japan:
Linical Company Limited
sales of 8.36 billion Japanese Yen [US$78.79 million]
of which 90%
was Cro Business),
Sosei Group Corporation
(18.90 billion Japanese Yen [US$178.24 million]
of which 99%
was Overseas Pharmaceutical Business), and
Morishita Jintan Co., Ltd.
(10.97 billion Japanese Yen [US$103.42 million]
of which 71%
was Health Care Business).
During the year ended March of 2017, sales at
Shin Nippon Biomedical Laboratories Ltd were ¥17.24 billion (US$162.62 million).
increase of 16.9%
versus 2016, when the company's sales were ¥14.75 billion.
Despite this increase, sales are still
below the level achieved in 2015, when Shin Nippon Biomedical Laboratories Ltd
reported sales of ¥17.84 billion.
Sales of Translational Research Project saw an increase
that was more than double the company's growth rate: sales were up
155.5% in 2017, from
¥9.46 million to ¥24.17 million.
Shin Nippon Biomedical Laboratories Ltd also saw significant increases in sales in
Clinical Business (up 71.6% to ¥3.65 billion)
Not all segments of Shin Nippon Biomedical Laboratories Ltd experienced an increase in sales in 2017:
sales of Other Businesses fell 44.4% to ¥4.07 million.
(However, this segment's sales were only a very small portion of the company's overall sales).
Shin Nippon Biomedical Laboratories Ltd also experienced decreases in sales in
Police Medi (down 18.8% to ¥662.02 million)